Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 8, 2001

View Archived Issues

Microcide reports results for Q2 2001

SkyePharma acquires interest in RTP Pharma

Allergan expands dermatology collaboration with Cytochroma

Novartis files Estradot in the European Union

Cell Genesys expands oncology pipeline with acquisition of Calydon

First kidney transplant patient enrolled in phase II trials of ISAtx-247

Noven signs product development agreement with Novartis for combination HRT patches

Genzyme receives marketing authorization for Fabrazyme

Questcor sells shares of common stock to Sigma-Tau

Novasite Pharmaceuticals and Aventis enter evaluation agreement

Endorex acquires CTD and adds two clinical-stage products to its pipeline

FDA grants fast track status to TransMID-107R for the treatment of brain cancer

Rigel and Novartis begin collaboration to discover antiangiogenic agents

Novel acylquinoline derivative developed for antiulcer applications

Mitsui Chemicals reports anilide derivatives useful as antiarrhythmic agents

Arizona State University scientists design new DNA reductive alkylating agents

Selective PDE5 inhibitors reported by scientists at Nippon Soda

Taisho patents compounds for treating bone or neurological diseases

Researchers at Sankyo identify new MMP inhibitors

Simultaneous filing of a Common Technical Document for Amevive in the U.S. and Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...